Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mypol is a brand of analgesic and antipyretic medications developed and marketed by Anhox Healthcare. The product line primarily features paracetamol (acetaminophen) as the active ingredient, available in various strengths and formulations including 650mg tablets and a 250mg/5ml pediatric syrup. Additionally, the brand includes Mypol-D, a combination product containing diclofenac and paracetamol. Paracetamol acts by inhibiting the synthesis of prostaglandins in the central nervous system, which helps in reducing fever and relieving mild to moderate pain associated with headaches, toothaches, body aches, and the common cold. Diclofenac, present in the Mypol-D formulation, provides additional anti-inflammatory and analgesic effects through the inhibition of cyclooxygenase enzymes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mypol.